Zeo Scientifix Inc (BPSR) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access BPSR Annual Income Statement →
The income statement data below highlights shifts in Zeo Scientifix Inc's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Apr 30 2026)
Q2 2026
(Jan 31 2026) (Oct 31 2025) (Jul 31 2025) (Apr 30 2025)
Revenues
Total Revenue2.58
Costs & Expenses
Cost of Goods and Services Sold0.53
Gross Profit2.06
Selling, Administration, Marketing2.57
Depreciation & Amortization0.00
Research & Development0.00
Other Operating Expense / -Income0.00
Total operating costs including COS3.09
Operating income / -loss-0.51
Interest Expense0.01
Net Interest Expense / -Income0.01
Other loss / -income-0.38
Total costs & expenses2.73
Income & Taxes
Income / -loss before income taxes-0.15
Income after income taxes-0.15
Income / -loss from continuing operations-0.15
Net income / -loss-0.15
Income / -loss to shareholder-0.15
EBIT-0.13
EBITD-0.12
EBITDA-0.12
Earnings Per Share
Basic EPS (excl. extra items)-0.02
Basic Net EPS-0.02
Basic shares outstanding (Mill. of Units)7.76
Diluted Net EPS-0.02
Diluted average shares (Mill. of Units)7.76
4 historic quarters locked

Sign in to unlock the full Zeo Scientifix Inc income statement history.

About Zeo Scientifix Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.